• Pulsed Field Ablation Remodels the Cardiac Microenvironment

  2026-08-20

  This study moves beyond lesion size to examine how pulsed field ablation (PFA) reshapes the ventricular cardiac microenvironment over time. Using a mouse model and single-nucleus RNA sequencing, the authors identify coordinated cellular stress and wound-healing responses that help explain selective myocardial ablation and controlled inflammation.

• Panobinostat in MLL-Rearranged ALL: Mechanism and Evidence

  2026-08-20

  A 2018 Leukemia study showed that the HDAC inhibitor panobinostat has in vivo anti-leukaemic activity in MLL-rearranged acute lymphoblastic leukaemia and linked this effect to suppression of the RNF20/RNF40/WAC–H2B ubiquitination axis. Its combined xenograft, pharmacological, molecular, and genetic evidence illustrates how epigenetic dependencies can be evaluated beyond cell viability alone.

• Oligo (dT) 25 Beads: Practical mRNA Workflow

  2026-08-19

  Oligo (dT) 25 Beads provide a magnetic workflow for enriching polyadenylated eukaryotic mRNA from total RNA or suitable animal and plant samples. They are not a universal RNA cleanup reagent and should not be used as the primary strategy for prokaryotic RNA or transcripts lacking an accessible polyA tail.

• NEDD4L–PRMT5 Axis in Colorectal Cancer Metastasis

  2026-08-19

  A 2025 Advanced Science study identifies the HECT E3 ligase NEDD4L as a suppressor of colorectal cancer liver metastasis through ubiquitin-mediated degradation of PRMT5. The work connects NEDD4L loss to enhanced AKT1 arginine methylation and AKT/mTOR signaling, providing a mechanistic framework for studying metastatic colonization and protein-stability control.

• Targeted mRNA Nanoparticles in Poststroke BBB Repair

  2026-08-18

  Gao and colleagues developed mannose receptor-targeted lipid nanoparticles that deliver IL-10 mRNA to ischemic brain regions and promote a protective microglial phenotype. In mouse stroke models, this feedback-based strategy reduced neuroinflammation, improved blood–brain barrier integrity, limited neuronal apoptosis, and preserved neurological function, while supporting a potentially wider treatment window.

• Jiawei Weijin Decoction Targets SPP1 in NSCLC

  2026-08-18

  Xu et al. combined network pharmacology, transcriptomics, LC-MS/MS, bioinformatics, and experimental validation to investigate how Jiawei Qianjin Weijin Decoction (JWWJD) affects non-small cell lung cancer. The study identifies SPP1 as a metastasis-associated target and curcumol as a principal active component, while also illustrating how computational predictions can be tested through cell, binding, and xenograft experiments.

• Mitoxantrone Targets the ERα DBD–LBD Interface

  2026-08-17

  Wang and colleagues identify mitoxantrone as a ligand for an underexplored allosteric interface between the estrogen receptor alpha DNA-binding and ligand-binding domains. The study shows that this interaction redistributes ERα, promotes proteasomal degradation, and suppresses endocrine-resistant ERα mutants through a mechanism distinct from the compound’s DNA damage activity.

• IDH1-R132H Autopalmitoylation in Cancer Cells

  2026-08-17

  A recent Nature Chemical Biology study identifies C269 autopalmitoylation as a mutation-specific regulator of IDH1-R132H. The work connects fatty acid availability with 2-hydroxyglutarate production, epigenetic remodeling, and transformation, while highlighting a hydrophobic pocket that may be therapeutically exploitable.

• Berberine, RXRα/PPARγ, and SASP in Atherosclerosis

  2026-08-16

  This reference study identifies an RXRα/PPARγ/NEDD4 pathway through which berberine suppresses senescence-associated secretory phenotype inflammation in macrophage-derived foam cells and atherosclerotic plaques. Its combination of mouse, cellular, transcriptomic, and macrophage-specific knockdown experiments links nuclear-receptor activity to ubiquitin-dependent control of the GATA4/p62 complex.

• Purmorphamine Workflows for Hedgehog Research

  2026-08-15

  Use Purmorphamine as a receptor-proximal Smoothened agonist to connect Hedgehog signaling with osteoblast differentiation, mesenchymal stem cell assays, and sensory biology. This practical guide combines dose planning, cross-species assay design, and troubleshooting for more reproducible pathway modulation.

• NMDA: From Excitotoxicity to Ferroptosis Assays

  2026-08-14

  NMDA (N-Methyl-D-aspartic acid) provides a receptor-specific way to investigate excitotoxic injury, calcium signaling, and oxidative damage. This guide connects NMDA model design with ferroptosis-focused readouts from a retinal glaucoma study, helping researchers choose more informative assays.

• NU7441 (KU-57788) in DNA Repair Research

  2026-08-14

  NU7441 (KU-57788) is a potent, selective DNA-PK probe for studying double-strand break repair, cell-cycle responses, and cancer-cell sensitization. This guide connects practical dosing and assay design with emerging PRKDC–PD-L1 biology while separating established evidence from translational hypotheses.

• APOC1 and Cyclopamine in Papillary Thyroid Carcinoma

  2026-08-13

  A 2026 Translational Oncology study identifies APOC1 as a pro-tumorigenic and immune-evasion-associated factor in papillary thyroid carcinoma and uses Connectivity Map analysis to nominate cyclopamine as a candidate treatment. The work further shows that APOC1 depletion sensitizes PTC cells to cyclopamine, providing a mechanistic rationale for combined target validation and pharmacological intervention.

• Niclosamide Workflows for STAT3 Cancer Research

  2026-08-13

  Niclosamide enables a structured evaluation of STAT3-linked growth inhibition, apoptosis, and cell-cycle effects across cancer models. This workflow separates reduced viability from true cell killing, helping researchers interpret responses more rigorously and troubleshoot solubility, timing, and pathway-readout issues.

• Anti Reverse Cap Analog for Reliable mRNA Assays

  2026-08-12

  Learn how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G (SKU B8175) can improve synthetic mRNA translation workflows that support cell viability, proliferation, cytotoxicity, and reprogramming studies. This scenario-based guide connects cap orientation, in vitro transcription parameters, assay controls, and evidence-based product selection.

8030 records 4/536 page Previous Next 12345 下5页 Last page